Sarepta Therapeutics, Inc. Message Board
-
Seeking Alpha 5/22/13 By:George RHO
All in all, our assumptions and projections would have to be considerably off the mark for MNKD stock not to have substantial upside potential. It should be noted, too, that our figures could prove to be very conservative. -
just bought also !
-
All In.
- Reply to
Great Article : Pricing A Highly Probable Takeover Of MannKind LINK
by terridiamond158 •May 22, 2013 10:00 AMthanks great article
- Reply to
Article : Yahoo’s Tumblr deal ‘a long-shot, will be a money loser. LINK
by supermanjoe •May 20, 2013 12:02 PMwill make the worst mistake list this week
- Reply to
FB is Like a Rubber Ball - Always Bounces Right Back.
by sharkman683 •May 20, 2013 11:30 AMlook at chart it sure does : ))) loaded the truck.
-
Yahoo Finance May 20, 2013
Price Target Summary
Median Target: 34.00High Target: 40.00
No. of Brokers: 28 - Reply to
CNN MONEY :. ADVERTISERS WILL NOT USE TIMBLR BECAUSE OF IT'S CONTENT. LINK
by tommyhill685 •May 20, 2013 2:01 PMgreat read.. says it's a dud. LOL advertisers won't even use it.
- Reply to
FB Beat Estimate/ Made 1.46 BILLION in Reveune w/ 30% Mobile Growth- UNDERvalued. LINKED
by raytrader362 •May 20, 2013 12:36 PMgive me a break.. it goes right back up everytime.
-
Great Article, Won't Let me Post.. Says bad buy and misguided, advertisers won't use because of it's content. Great Read Just Google Title into Google.
Article :All Yahoo's spending can't make it cool again
May 20, 2013
It's time for the Web 1.0 icon to put down its credit card and get back to work.
By Cyrus Sanati - Reply to
I Suspect Big Run Up Before Asco. / Asco May 31, 2013 |Chicago, Illinois
by moneyandstocks •May 15, 2013 5:10 PMgreat news out after hours my friend.
-
Experimental Gilead drug effective in early-stage leukemia trial Reuters
Wed May 15, 2013 5:59pm EDT
By Deena Beasley
May 15 (Reuters) - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
The pill, idelalisib, is part of a new class of medications designed to selectively block a type of protein known to promote tumor growth in patients with chronic lymphocytic leukemia (CLL) and other types of blood cancer.
The "pretty incredible" results illustrate how a growing understanding of tumor biology is helpingresearchers develop promising new targeted drugs, said Dr Sandra Swain, president of the American Society of Clinical Oncology, which will feature the research at its conference in Chicago later this month. - Reply to
Been Waiting To Get In All Day. Thanks Great Entry Point.
by pressman_john •May 15, 2013 3:15 PMI disagree, big news out after hours and run up for Asco, we are just getting started.
- Reply to
This Is It. FDA Can Make Decision When Get Documents This Month.
by going1green •May 9, 2013 10:09 AMnow it gets exciting !
-
5/9/13 Earnings Yahoo Finance
- Reply to
Last statement by Chris: the FDA is our partner in getting this drug to patients as soon as possible.
by shimp41 •May 9, 2013 9:31 AMjust posted it too
-
Yahoo News 5/9/13
Best comment by CG: We believe the FDA will partner with us to get this product to patients who need it -
wouldn't add suppliers if drug sales were down.